Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of ...

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

A worldwide health crisis now threatens individuals from all age brackets, thanks to the rise of obesity as a pandemic. The medical condition results when accumulated body fat exceeds safe levels ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

At the time, Hsieh noted that Viking’s results exceeded Wall Street expectations and outperformed Novo Nordisk’s experimental weight-loss pill, amycretin. “Notably, the 100 mg dose appears ...

Morgan Stanley argues that key debates from REDEFINE-1 remain, and says that the clinical profile similar to tirzepatide increases the importance of amycretin as a next-gen molecule to sustain the ...